They analyzed the potential prognostic impact of 360 proteomic markers, including SLAMF3/CD229, on the clinical outcomes of 51 elderly patients and young frail patients with advanced CLL treated with front-line chemoimmunotherapy involving chlorambucil, rituximab, and lenalidomide. This evidence concerns the gene LY9 and B-cell chronic lymphocytic leukemia.